Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction Tools

The goal of this study was to design, experimentally validate, and apply a virtual screening workflow to identify novel hERG channel blockers. The hERG channel is an important antitarget in drug development since cardiotoxic risks remain as a major cause of attrition. A ligand-based pharmacophore model collection was developed and theoretically validated. The seven most complementary and suitable models were used for virtual screening of in-house and commercially available compound libraries. From the hit lists, 50 compounds were selected for experimental validation through bioactivity assessment using patch clamp techniques. Twenty compounds inhibited hERG channels expressed in HEK 293 cells with IC50 values ranging from 0.13 to 2.77 μM, attesting to the suitability of the models as cardiotoxicity prediction tools in a preclinical stage.

[1]  Anthony E. Klon,et al.  Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development , 2010, Expert opinion on drug metabolism & toxicology.

[2]  Seong Jun Park,et al.  Bioactive sulfoximines: syntheses and properties of Vioxx analogs. , 2011, Bioorganic & medicinal chemistry letters.

[3]  Yuko Ohno,et al.  Pharmacophore modeling for hERG channel facilitation. , 2012, Biochemical and biophysical research communications.

[4]  Paul Czodrowski,et al.  hERG Me Out , 2013, J. Chem. Inf. Model..

[5]  Klaus R. Liedl,et al.  One Concept, Three Implementations of 3D Pharmacophore-Based Virtual Screening: Distinct Coverage of Chemical Search Space , 2010, J. Chem. Inf. Model..

[6]  Michael C Sanguinetti,et al.  Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. , 2003, Molecular pharmacology.

[7]  C R Benedict,et al.  Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. , 2000, The Journal of pharmacology and experimental therapeutics.

[8]  J. Hancox,et al.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline , 1999, British journal of pharmacology.

[9]  Amiram Goldblum,et al.  Indexing molecules for their hERG liability. , 2013, European journal of medicinal chemistry.

[10]  Scott Boyer,et al.  Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data , 2007, J. Comput. Aided Mol. Des..

[11]  Bo-Han Su,et al.  In Silico Binary Classification QSAR Models Based on 4D-Fingerprints and MOE Descriptors for Prediction of hERG Blockage , 2010, J. Chem. Inf. Model..

[12]  Ying Xue,et al.  Identifying hERG Potassium Channel Inhibitors by Machine Learning Methods , 2008 .

[13]  Steffen Hering,et al.  State-dependent dissociation of HERG channel inhibitors , 2007, British journal of pharmacology.

[14]  Mark L Dallas,et al.  Robotic multiwell planar patch-clamp for native and primary mammalian cells , 2009, Nature Protocols.

[15]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[16]  Thomas Seidel,et al.  Strategies for 3D pharmacophore-based virtual screening. , 2010, Drug discovery today. Technologies.

[17]  Anthony Nicholls,et al.  Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures , 2012, J. Chem. Inf. Model..

[18]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[19]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[20]  A. Hoes,et al.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.

[21]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[22]  Y. Kurachi,et al.  Inhibitory effects of vesnarinone on cloned cardiac delayed rectifier K(+) channels expressed in a mammalian cell line. , 2000, The Journal of pharmacology and experimental therapeutics.

[23]  Thierry Langer,et al.  Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) Inhibitors , 2006, J. Chem. Inf. Model..

[24]  Maurizio Recanatini,et al.  hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.

[25]  Youyong Li,et al.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. , 2012, Molecular pharmaceutics.

[26]  Siobhan Malany,et al.  Novel benzothiophene H1-antihistamines for the treatment of insomnia. , 2010, Bioorganic & medicinal chemistry letters.

[27]  Serdar Durdagi,et al.  Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding , 2012, J. Chem. Inf. Model..

[28]  A. Bianucci,et al.  Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands. , 2013, Journal of molecular graphics & modelling.

[29]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[30]  Max K Leong,et al.  A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability. , 2007, Chemical research in toxicology.

[31]  Serdar Durdagi,et al.  Combined Receptor and Ligand-Based Approach to the Universal Pharmacophore Model Development for Studies of Drug Blockade to the hERG1 Pore Domain , 2011, J. Chem. Inf. Model..

[32]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[33]  R. Peri,et al.  High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology , 2008, Nature Reviews Drug Discovery.

[34]  Andreas Bender,et al.  Prospective Validation of a Comprehensive In silico hERG Model and its Applications to Commercial Compound and Drug Databases , 2010, ChemMedChem.

[35]  I. Baburin,et al.  Automated fast perfusion of Xenopus oocytes for drug screening , 2006, Pflügers Archiv.

[36]  Daniela Schuster,et al.  3D pharmacophores as tools for activity profiling. , 2010, Drug discovery today. Technologies.

[37]  Gary R. Mirams,et al.  Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge , 2013, Journal of pharmacological and toxicological methods.

[38]  Walter Sandtner,et al.  Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile☆ , 2013, Toxicology and applied pharmacology.

[39]  Alex M Aronov,et al.  Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.

[40]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[41]  X. Wan,et al.  hERG channel trafficking: novel targets in drug-induced long QT syndrome. , 2007, Biochemical Society transactions.

[42]  C. January,et al.  Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. , 2001, Molecular pharmacology.

[43]  J. Valentin,et al.  In vitro models of proarrhythmia , 2008, British journal of pharmacology.

[44]  Liudmila Polonchuk,et al.  Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner® , 2012, Front. Pharmacol..

[45]  W. Crumb,et al.  Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. , 2000, The Journal of pharmacology and experimental therapeutics.

[46]  Sebastian Polak,et al.  Prediction of the hERG potassium channel inhibition potential with use of artificial neural networks , 2011, Appl. Soft Comput..

[47]  Christopher W. Jenks,et al.  Extraction Studies of Tabernanthe Iboga and Voacanga Africana , 2002, Natural product letters.

[48]  Daniela Schuster,et al.  Predicting Cyclooxygenase Inhibition by Three‐Dimensional Pharmacophoric Profiling. Part I: Model Generation, Validation and Applicability in Ethnopharmacology , 2010, Molecular informatics.

[49]  T J Campbell,et al.  Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate , 1999, British journal of pharmacology.

[50]  T. Erker,et al.  Trapping and dissociation of propafenone derivatives in HERG channels , 2011, British journal of pharmacology.

[51]  T J Campbell,et al.  Inhibition of HERG potassium channels by the antimalarial agent halofantrine , 2000, British journal of pharmacology.

[52]  Adriaan P IJzerman,et al.  Understanding of Molecular Substructures that Contribute to hERG K+ Channel Blockade: Synthesis and Biological Evaluation of E‐4031 Analogues , 2012, ChemMedChem.

[53]  Lu Chen,et al.  A Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Channel Blocker Modeling , 2011, J. Chem. Inf. Model..

[54]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[55]  Sichao Wang,et al.  Recent developments in computational prediction of HERG blockage. , 2013, Current topics in medicinal chemistry.

[56]  Ki-Suk Kim,et al.  The Phenothiazine Drugs Inhibit hERG Potassium Channels , 2005, Drug and chemical toxicology.

[57]  Stephen R. Johnson,et al.  Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR. , 2007, Bioorganic & medicinal chemistry.

[58]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[59]  Sharad Verma,et al.  Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines. , 2010, Bioorganic & medicinal chemistry letters.

[60]  Stefan A. Mann,et al.  hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.

[61]  Gary R. Mirams,et al.  Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials , 2013, British journal of pharmacology.

[62]  Marcus J. Drake,et al.  The Validation of a Functional, Isolated Pig Bladder Model for Physiological Experimentation , 2012, Front. Pharmacol..

[63]  R. Sedrani,et al.  Direct renin inhibitors as a new therapy for hypertension. , 2010, Journal of medicinal chemistry.

[64]  Yadong Chen,et al.  Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models , 2012, Journal of Molecular Modeling.

[65]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[66]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[67]  Daniela Schuster,et al.  Pharmacophore Model Refinement for 11β‐Hydroxysteroid Dehydrogenase Inhibitors: Search for Modulators of Intracellular Glucocorticoid Concentrations , 2014, Molecular informatics.

[68]  Jacob de Vlieg,et al.  Comparative Analysis of Pharmacophore Screening Tools , 2012, J. Chem. Inf. Model..

[69]  Thierry Langer,et al.  Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..

[70]  Kelly Rae Chi.  Revolution dawning in cardiotoxicity testing , 2013, Nature Reviews Drug Discovery.

[71]  Siobhan Malany,et al.  Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia. , 2009, Bioorganic & Medicinal Chemistry Letters.

[72]  Raimund Mannhold,et al.  QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability. , 2012, Molecular pharmaceutics.